FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
New study presents a human-relevant stress model for assessing potential therapeutics
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
Max and Luna personify HRV Pharma’s core values of trust, loyalty, and authentic partnership
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
Stephan brings more than 20 years of leadership experience in the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
